Khloris Biosciences is a biotech company based in the Bay Area that aims to transform the medical treatment of cardiovascular and other high unmet need diseases. They have developed a proprietary platform of disease-specific induced pluripotent stem cells (iPSCs) for innovative drug screening and discovery. Additionally, Khloris Biosciences is actively working on next-generation oncology vaccines that can cure and prevent various types of cancer. Their vaccines leverage pluripotent stem cells (PCs) to trigger a robust immune response, involving both innate and adaptive immune cells. This approach not only provides reliable cancer treatment but also improves the overall health of patients.